VYGR
insider transactionsVoyager Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-80.2K
0 buy · 80.2K sell
Net value · 365d
-$298.0K
$0 in · $298.0K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
11
0 buy · 80.2K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
Own New
-
Grant·A
Director
$0
30.0K sh
-
Sell·S
Alfred Sandrock KEY
President and CEO · 10b5-1
$44.5K
11.5K sh · $3.87
Own -2%
-
Grant·A
SVP and General Counsel
$0
50.0K sh
Own New
-
Sell·S
COO & CBO · 10b5-1
$24.3K
6.5K sh · $3.77
Own -3%
-
Sell·S
Alfred Sandrock KEY
President and CEO · 10b5-1
$53.8K
14.2K sh · $3.79
Own -3%
-
Sell·S
Chief Financial Officer · 10b5-1
$17.6K
4.7K sh · $3.77
Own -3%
-
Sell·S
Chief Scientific Officer · 10b5-1
$15.7K
4.2K sh · $3.76
Own -3%
-
Sell·S
COO & CBO · 10b5-1
$13.4K
3.9K sh · $3.44
Own -2%
-
Sell·S
Alfred Sandrock KEY
President and CEO · 10b5-1
$40.0K
11.7K sh · $3.41
Own -2%
-
Sell·S
Chief Scientific Officer · 10b5-1
$11.4K
3.3K sh · $3.44
Own -2%
-
Sell·S
COO & CBO
$17.6K
4.6K sh · $3.85
Own -2%
-
Sell·S
Alfred Sandrock KEY
President and CEO
$46.1K
12.2K sh · $3.78
Own -2%
-
Sell·S
Chief Scientific Officer
$13.6K
3.5K sh · $3.85
Own -2%
-
Grant·A
COO & CBO
$0
210.0K sh
Own New
-
Grant·A
COO & CBO
$0
45.0K sh
Own +27%
-
Grant·A
Alfred Sandrock KEY
President and CEO
$0
402.5K sh
Own New
-
Grant·A
Alfred Sandrock KEY
President and CEO
$0
86.2K sh
Own +20%
-
Grant·A
Chief Financial Officer
$0
150.5K sh
Own New
-
Grant·A
Chief Financial Officer
$0
32.2K sh
Own +26%
-
Grant·A
Chief Medical Officer
$0
210.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
45.0K sh
Own +32%
-
Grant·A
Chief Scientific Officer
$0
154.0K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
33.0K sh
Own +27%
-
Grant·A
SVP and General Counsel
$0
100.0K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 9, 2026 | Nancy Vitale | Grant A | 30.0K | $0 |
| Jun 9, 2026 | George A Scangos | Grant A | 30.0K | $0 |
| Jun 9, 2026 | Glenn Pierce | Grant A | 30.0K | $0 |
| Jun 9, 2026 | Jude Onyia | Grant A | 30.0K | $0 |
| Jun 9, 2026 | Catherine J Mackey | Grant A | 30.0K | $0 |
| Jun 9, 2026 | Steven Hyman | Grant A | 30.0K | $0 |
| Jun 9, 2026 | Michael J Higgins | Grant A | 30.0K | $0 |
| Jun 9, 2026 | James A Geraghty | Grant A | 30.0K | $0 |
| Jun 9, 2026 | Grace Colon | Grant A | 30.0K | $0 |
| Apr 2, 2026 | Alfred Sandrock KEY 10b5-1 | Sell S | 11.5K | $44.5K |
| Apr 1, 2026 | Gregory L. Shiferman | Grant A | 50.0K | $0 |
| Feb 24, 2026 | Robin Swartz 10b5-1 | Sell S | 6.5K | $24.3K |
| Feb 24, 2026 | Alfred Sandrock KEY 10b5-1 | Sell S | 14.2K | $53.8K |
| Feb 24, 2026 | Nathan D. Jorgensen KEY 10b5-1 | Sell S | 4.7K | $17.6K |
| Feb 24, 2026 | Todd Alfred Carter 10b5-1 | Sell S | 4.2K | $15.7K |
| Feb 18, 2026 | Robin Swartz 10b5-1 | Sell S | 3.9K | $13.4K |
| Feb 18, 2026 | Alfred Sandrock KEY 10b5-1 | Sell S | 11.7K | $40.0K |
| Feb 18, 2026 | Todd Alfred Carter 10b5-1 | Sell S | 3.3K | $11.4K |
| Feb 10, 2026 | Robin Swartz | Sell S | 4.6K | $17.6K |
| Feb 10, 2026 | Alfred Sandrock KEY | Sell S | 12.2K | $46.1K |
| Feb 10, 2026 | Todd Alfred Carter | Sell S | 3.5K | $13.6K |
| Feb 6, 2026 | Robin Swartz | Grant A | 210.0K | $0 |
| Feb 6, 2026 | Robin Swartz | Grant A | 45.0K | $0 |
| Feb 6, 2026 | Alfred Sandrock KEY | Grant A | 402.5K | $0 |
| Feb 6, 2026 | Alfred Sandrock KEY | Grant A | 86.2K | $0 |
| Feb 6, 2026 | Nathan D. Jorgensen KEY | Grant A | 150.5K | $0 |
| Feb 6, 2026 | Nathan D. Jorgensen KEY | Grant A | 32.2K | $0 |
| Feb 6, 2026 | Toby Ferguson | Grant A | 210.0K | $0 |
| Feb 6, 2026 | Toby Ferguson | Grant A | 45.0K | $0 |
| Feb 6, 2026 | Todd Alfred Carter | Grant A | 154.0K | $0 |
| Feb 6, 2026 | Todd Alfred Carter | Grant A | 33.0K | $0 |
| Jan 6, 2026 | Gregory L. Shiferman | Grant A | 100.0K | $0 |
About VYGR insider trading
This page tracks insider transactions for Voyager Therapeutics, Inc. (VYGR) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.